An exciting paper was recently published in Cancer Discovery highlighting the promise of the recently FDA approved FGFR inhibitor drugs for an even broader population of cholangiocarcinoma patients with FGFR2 fusions. The Evan Schumacher Fund for Rare Cancer Research at TargetCancer Foundation directly supported Dr. James Cleary’s work at Dana-Farber Cancer Institute leading to these important developments. His work was also informed by TCF’s longstanding commitment to cell line creation for cholangiocarcinoma, beginning over a decade ago in Dr. Nabeel Bardeesy’s lab at Massachusetts General Hospital.
It is tremendously meaningful to see the impacts of TCF’s initial commitment to cholangiocarcinoma research on the progress being made today. We are so proud to be a part of this work and congratulate Dr. Cleary on this important publication.
Click below to watch a short video published by Dana-Farber of Dr. Cleary summarizing the paper.